OCUL
NASDAQ · Pharmaceuticals
Ocular Therapeutix Inc
$9.43
-0.21 (-2.18%)
Financial Highlights (FY 2026)
Revenue
59.44M
Net Income
-304,214,720
Gross Margin
87.3%
Profit Margin
-511.9%
Rev Growth
+0.3%
D/E Ratio
0.11
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 87.3% | 87.3% | 60.7% | 60.7% |
| Operating Margin | -519.7% | -467.8% | 16.1% | 19.8% |
| Profit Margin | -511.9% | -486.3% | 14.8% | 14.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 59.44M | 59.26M | 384.00M | 364.41M |
| Gross Profit | 51.92M | 51.76M | 232.96M | 221.08M |
| Operating Income | -308,928,246 | -277,203,809 | 61.85M | 72.20M |
| Net Income | -304,214,720 | -272,974,325 | 56.73M | 50.92M |
| Gross Margin | 87.3% | 87.3% | 60.7% | 60.7% |
| Operating Margin | -519.7% | -467.8% | 16.1% | 19.8% |
| Profit Margin | -511.9% | -486.3% | 14.8% | 14.0% |
| Rev Growth | +0.3% | +0.3% | -3.5% | -8.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 101.47M | 101.47M | 542.51M | 619.03M |
| Total Equity | 930.93M | 930.93M | 1.53B | 1.48B |
| D/E Ratio | 0.11 | 0.11 | 0.35 | 0.42 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -303,936,272 | -287,875,830 | 95.97M | 85.28M |
| Free Cash Flow | — | — | 61.23M | 57.18M |